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ABSTRACT 
Obesity is the inappropriate accumulation of excess fat stored in the adipocytes of the adipose 
tissue. Understanding the molecular mechanisms that regulate the process of preadipocyte to 
adipocyte conversion, adipogenesis, is crucial when trying to design treatments for the 
disease. Known transcription factors, such as Peroxisome proliferator-activated receptor y 
(PPARy), play an essential role in preadipocytes differentiation into adipocytes. However, 
more recently novel nuclear receptors such as, Brn-3b (or POU4F2, second transcription 
factor in the fourth class of POU family), have been shown to be expressed in adipose tissue, 
but their link with adipogenesis is yet to be established. 3T3-Lls, a murine adipocyte cell-
line, was used to investigate Brn3b gene expression during adipogenesis in high and low 
glucose conditions, in the presence and absence of dexamethasone, and compared to PP ARy 
gene expression. Two experiments with high glucose were performed one in the presence of 
dexamethasone and the other without dexamethasone. A third experiment was conducted 
using low glucose with dexamethsone. RNA extracted from cells at different time intervals 
was converted to eDNA before being analyzed by qPCR. Morphological examination of the 
cells confirmed the requirement of high glucose concentrations for cells to differentiate into 
adipocytes. There was significant increase in PPARy gene expression during adipogenesis of 
cells grown in high glucose concentration in presence or absence of dexamethasone. 
However, no detectable expression of Brn-3b was apparent in either the preadipocytes or the 
adipocytes, under any of the experimental conditions studied. These results suggest that the 
expression of Brn-3b in adipose tissue derives from the non-adipocyte cells of the tissue, such 
as neuronal, endothelial, monocytic or epithelial. 
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INTRODUCTION 
As obesity is becoming more prevalent worldwide and associated with many metabolic 
disorders like type2 diabetes and cardiovascular diseases, many scientists turned their interest 
towards research into understanding the causes and consequences of obesity. Obesity has 
been studied not only clinically, but also at the molecular level. Many transcription factors 
have been investigated and some were linked to adipose tissue, like PPARy. Brn3b is a 
transcription factor that has been studied extensively in nervous tissue and retinal ganglion 
cells. However, recent unpublished data, interestingly, revealed that Brn3b knockout mice had 
higher body weights and there was detectable expression of this nuclear receptor in murine 
adipose tissue. Furthermore, in a comparison between obese type 2 diabetic (T2DM) and 
healthy normal weight people, Brn3b mRNA was detected in peripheral blood cells and found 
to decrease more than one and half folds in diabetics. The findings of this unpublished study 
raised a question of the possibility ofBrn3b involvement in obesity and diabetes. 
Brn3b gene expression was investigated and compared to PPARy gene, using 3T3-Ll cell line 
as a metabolically active adipocytes cellular model. 3T3-Ll cells were treated with high and 
low glucose concentrations in the presence of insulin. Data showed increased PP ARy gene 
expression during differentiation of preadipocytes into adipocytes in high glucose treatment, 
with or without dexamethasone, while no such changes were seen when using low glucose 
treatment. However, Brn-3b was not detected under any of these conditions in these cells. 
1 
LITERATURE REVIEW 
Obesity 
Obesity or overweight is defined according to Centers for Disease Control and Prevention 
(CDC) as: "Overweight and obesity are both labels for ranges of weight that are greater than 
what is generally considered healthy for a given height. The terms also identify ranges of 
weight that have been shown to increase the likelihood of certain diseases and other health 
problems." (CDC, 2012). 
Obesity is also defined as the increase of body weight due to abnormal fat accumulation and 
is related to increased risk of many diseases such as diabetes mellitus (The Free Dictionary, 
2014). 
Obesity IS becoming more prevalent all around the world, increasing the need for 
understanding the underlying etiologies. According to WHO, obesity has nearly doubled in 
the past thirty years (WHO, 2014). 
High energy intake and with lower physical activity, and therefore energy expenditure 
accounts for the overweight and obesity state spreading all over the world. Chronic obesity 
increases the risk for many diseases such as: cardiovascular hemodynamics (Lavie et al, 
2014), kidney related diseases like obesity-related glomerulopathy (Ross & McGill, 2006), 
metabolic disorders such as type 2 diabetes mellitus and fatty liver disease, other morbidities 
like obstructive sleep apnea, dementia, and even several types of cancer (Bliiher, 2013 ). 
Fat cells are known as adipocytes, which contribute to around 50% of the cells of the adipose 
tissue. Adipose tissue is areolar connective tissue that maintains body temperature, attaches 
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skin to the beneath tissue, and shields body organs. Generally, adipose tissue includes two 
types, white adipose tissue (W AT) and brown adipose tissue (BAT). Each type has its specific 
characteristics; white adipose tissue serves as an energy reservoir, where triglycerides are 
stored in large lipid droplets (Lafontan, 2008). Also, recent studies have found that white 
adipose tissue can be considered as an endocrine and paracrine organ which produces 
chemicals similar to hormones called adipokines that can affect many body functions like 
thyroid, blood pressure, immune responses, and even reproductive systems (Trayhurn, 2005). 
On the other hand, brown adipose tissue is rich in mitochondria and mainly functions for heat 
generation by fatty acid oxidation. Unlike white adipose tissue, triglycerides in brown adipose 
tissue are distributed over multiple small lipid droplets (Cannon & Nedergaard, 2004). White 
and brown adipose tissues are also distributed differently. White adipose tissue (WAT) 
predominates in adult humans, but brown adipose tissue (BAT) mainly found in newborns 
and rodents. Studies have shown that white adipose tissue (W AT) is the one responsible for 
obesity status and its related complications like type2 diabetes mellitus. The reason for that is 
brown adipose tissue (BAT) produces less adipokines (Farmer, 2008). Furthermore, studies 
found that dysregulation of white adipose tissue (WAT) function leads to hyperglycemia and 
hyperlipidemia, which ultimately cause insulin resistance and chronic inflammation 
0 (Trayhurn, 2005). 
Adipocytes 
Adipocytes thought to be originating from mesenchymal stem cells, but still many steps 
among the commitment process are unclear (Guilak et al, 2006). However, other studies claim 
the potential of neuroepithelial cells to form mature adipocytes (Takashima et al, 2007). Even 
bone marrow progenitors may be converted into adipocytes that can be differently 
accumulated according to age and weight (Rodeheffer et al., 2008; Tang et al., 2009). 
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The process of fibroblast-like preadipocytes differentiation into mature lipid laden, insulin-
responsive adipocytes, is known as "Adipogenesis" (Lefterova & Lazar, 2009). Preadipocytes 
have a similar morphology to fibroblasts; however, when they differentiate into mature 
adipocytes, they become round puffy cells with large fat droplet pushing nucleus to the border 
and making cytoplasm condensed in a thin layer (Ali et al, 2013). 
(Ali et al, 20 13) 
Fibroblast Develo ing Preadipocyte Immature Adipocyte Mature Adipoc te 
Figure I Adipocyte differentiation. The reverse arrows represent the possibility of adipocytes to reduce size 
when energy supply diminishes. 
Adipogenesis process ends up with mature adipocytes that have gone through the main stages 
of differentiation. It starts with mesenchymal precursors becoming committed preadipocytes 
that undergo growth arrest until they start dividing again and clonally expand before they 
ultimately differentiate and become mature adipocytes (Lefterova and Lazar, 2009). 
As adipogenesis is the main process in obesity state, scientists found adipogenesis an 
appealing subject for research and study. Adipogenesis has been studied extensively for the 
past 40 years (Ali et al, 2013); on different levels, in vivo and in vitro using preadipocytes cell 
line. The changes in preadipocytes, induced by their differentiation, on both their morphology 
and gene expression are studied. Several transcription factors involved in adipogenesis has 
been identified; however, many others are still unknown. Among the recognized transcription 
factors strongly associated with adipogenesis, peroxisome proliferator-activated receptor y 
(PPARy), the transcriptional factor sterol-regulatory-element-binding-protein-1 (SREBPI ), 
macrophage colony stimulating factor, insulin-like growth factor I (IGF-1), interferon 
regulatory factors IRFs (IRF3 and IRF4), fibroblast growth factors, pro-inflammatory 
cytokines, hypoxia and others. Moreover, in sake of preventing adipocytes accumulation, 
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adipogenesis inhibitors has been identified like glycoproteins, inflammatory cytokines, 
transforming growth factor-P (TGF-p), and growth hormone (Ali et al, 2013). 
Peroxisome Proliferator-Activated Receptor y (PP ARy) 
Peroxisome proliferator-activated receptor y (PPARy) is considered one of the most famous 
transcription factors related to adipogenesis. PP ARy belongs to the nuclear receptor (NR) 
super-family of ligand-dependent transcription factors (TFs) (Poulsen et al, 2012). Early 
studies have shown that PPARy is essential in adipogenesis (Tontonoz et al, 1994). A study 
has shown that PPARy knockout mice cannot survive embryonic stage due to placental 
defects, while chimeric PPARy mice showed inability of cells missing PPARy for 
involvement in fat formation (Barak et al, 1999) (Rosen et al, 1999). 
PP ARy is encoded by PP ARg gene (PP ARG/Pparg) that is translated into two proteins 
PPARyl and PPARy2; and mainly expressed in adipocytes (Poulsen et al, 2012). PPARy 
structure is divided into three domains: N-terminal domain, DNA binding domain, and C-
terminal ligand-binding domain (Tontonoz & Spiegelman, 2008). PPARy has the ability to 
bind to its binding site without a ligand; such binding leads to suppression of transcription. On 
the contrary, binding of PPARy to its ligand leads to activation of gene transcription 
0 (Tontonoz & Spiegelman, 2008). Genes involved in fatty acid (FA) and glucose metabolism 
contain binding sites for PPARy, which points to the involvement of PPARy in metabolic 
pathways of adipogenesis (Mikkelsen et al 201 0). 
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In order for transcription factors, in general, to work; they need chromatin to be opened and 
nucleosome become free. Therefore, transcription factors accessibility to DNA is governed by 
chromatin remodeling complexes (Clapier & Cairns, 2009). In a study of adipocyte 
differentiation held on 3T3-L1 cells, a great change in chromatin structure has been observed 
during early adipogenesis (Siersbrek et al, 2011 ). Furthermore, big differences have been 
found, in another study, in comparison of chromatin structure of 3T3-L1 mature and 
preadipocytes (Waki et al, 2011). Transcription factors have an influence on the action of 
each other through chromatin remodeling. For example, C/EBPP is an early acting 
0 transcription factor that can open sites for other transcription factors such as PPARy. C/EBPP 
can also bind to partially closed chromatin (Siersbrek et al, 2011). 
.... :::> 
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Figure 2 Transcriptional network during adipogenes~wo waves of transcription factors (TFs) activation occur 
during adipocyte differentiation. Second wave TFs, including PPARy are activated by first wave TFs that in 
their tum have been activated by adipogenic cocktail. Whole process is accompanied by chromatin 
remodeling to open sites for TFs. 
It has been noticed that, in a number of cell types, PP ARy binding sites exhibit open 
chromatin, on the contrary, sites specific for PPARy role in adipocytes are made available 
subsequently throughout adipogenesis (Oger et al, 2014). Whole PPARy locus and other 
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adipocyte gene loci in 3T3-Ll preadipocytes are repressed by H3K9me2, a histone mark; 
such repression is lifted by the adipogenic cocktail (Wang et al, 2013). 
In a comparison between mouse and human PP ARy binding sites in adipocytes, studies 
showed that only few sites are shared, estimated to be about 9%-30% (Soccio et al, 2011) 
(Mikkelsen et al, 201 0). 
In an experiment for diabetes management, synthetic PP ARy agonists have been used; 
nevertheless, that experiment was not quit successful owing to dangerous consequences 
leading to activation ofPPARy in non adipose tissues (Cariou et al, 2012). 
POU (Pit-Oct-Unc) Transcription Factors 
There is multiple transcription factors involved in many vital processes in body organs; Bm3b 
is one of those transcription factors. Bm3b belongs to POU (Pit-Oct-Unc) transcription 
factors family, which are expressed in a range of tissues especially nervous tissue and 
embryonic cells. POU name comes from the first transcription factors discovered in the 
family; Pitl, Oct 1, and Oct2. Oct2 is found in mammalians, which is the same as Unc86 
found in Caenorhabditis elegans (Herret et al., 1988). Pit1 stands for pituitary and is involved 
in pituitary growth; whereas Octl is known as that because it binds to octamer motif of DNA 
and promotes gene transcription of histones and immunoglobulins. Bm3b also known as 
POU4F2 since it is the second transcription factor in the fourth class of POU family. Bm3b, 
known also as Bm-3.2 : 6, originally was isolated, using reverse transcriptase polymerase 
chain reaction (RT/PCR), from ND7 neuronal cell line (Lillycrop et al, 1992). The significant 
function of Bm3b in visual system development is shown when a Bm3b knockout in mice 
resulted in great retinal abnormalities (Erkman et al, 1996). In another study on retina, 70 % 
of retinal ganglion cells were missing in Bm3b knockout mice due to abnormal axon growth 
and ultimate cell death (Wang et al. , 2000). Although Bm3b initially discovered and 
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predominantly present in neuronal cells, Bm3b is also found in many other cell types such as: 
breast cells, testis, retina, and peripheral blood cells (Ounzain et al, 2011) (Budhram-Mahadeo 
et al, 2001) (Xiang et al, 1993) (Niculescu et al, 2007). 
Bm3b, as a transcription factor, can control the expression of many genes responsible for 
variable cellular processes. Bm3b found to promote cell cycle progression genes such as 
cyclin-dependent kinase 4 (CDK4) (Samady et al, 2004), and a regulator cyclin Dl 
(Budhram-Mahadeo et al, 2008). In general, Bm3b found to promote cell division and even 
increase tumor growth (Irshad et al, 2004). 
3T3-Ll Cell Line 
Cell lines have been used by scientists for decades in research and scientific experiments. 
Multiple cell lines are available with a variety of characteristics that can be specified by 
scientists according to the scientific experiment to be held. 
3T3-Ll cell line has been used for over three decades now in research. 3T3-Ll cells are 
derived from Swiss mouse fibroblasts 3T3 cells, and have the potential, in appropriate 
conditions, to differentiate into mature adipocytes. 3T3-Ll cells were originally discovered 
by Green and Kehinde in 1974, from 3T3-M cells that have been isolated and frozen from 
Swiss embryo cells. Green and Kehinde noticed that 3T3-Ll cells, when in resting state, can 
accumulate triglycerides. In addition, lipid distribution in 3T3-L 1 cells was similar to that of 
brown adipose tissue; where small distributed fat droplets were seen in a plentiful cytoplasm 
with central nucleus (Green & Meuth, 1974). 
Through their experiments, Green and Meuth, noticed that in order for the cells to go into 
resting state that allow them to start differentiation cells need to be in a confluent monolayer 
first. However, trypsin could be used to arrest cells at any time along with using methyl 
cellulose in medium and calf serum at concentration of 30% (Stoker, 1968). 
8 
0 
An advantage of 3T3-Ll cell line is that they are immortalized, and can be passaged and 
frozen to keep a constant source of cells through experiments. Nevertheless, the negative side 
of 3T3-L 1 cells is that after many passages their potential to differentiate drops. Another 
drawback not only of 3T3-Ll alone, but generally when applying experimental changes on a 
cell line, cells are in a biological and molecular condition differs from that of living tissues 
(Ntambi & Y oung-Cheul, 2000). 
Since that time until now 3T3-L 1 cells have been used extensively in research as 
preadipocytes that can differentiate into adipocytes. More specifically, 3T3-Ll cells have 
been used in experiments related to obesity and diabetes. 
Hypothesis 
Building upon the unpublished interesting findings by Dr. Vidya Mohamed-Ali and 
colleagues, which found that Brn3b knockout mice had a higher body weights; and, diabetic 
obese patients had reduced Brn3b mRNA in peripheral blood (Hindle et a!., 2010) (see 
appendix IV). We hypothesize that Brn3b transcription factor may contribute for the 
regulation of metabolic processes linked to obesity and its consequences. Brn3b gene 
expression change might be associated with the differentiation of preadipocytes into 
adipocytes; hence Brn3b might be involved in obesity. 
Aim 
The main aim of this study is to investigate if the adipocytes-in vitro- has the expression of 
Brn3b in a model of metabolically active cell line, murine 3T3-Ll adipocytes, and to compare 
it with the expression of PPARy; in sake of elucidating mechanisms by which Brn3b may 
influence adipogenesis and obesity. 
Specific Aims: 
9 
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1- To study and compare mRNA gene expression ofboth Brn3b and PPARy during 3T3-
Ll cell differentiation from preadipocytes into adipocytes at different time intervals 
(at days 0, 3, 5, and 7). 
2- To examine the effect of low glucose concentration on gene expression of Brn3b and 
PPARy during adipogenesis at the same time intervals (days 0, 3, 5, and 7). 
3- To explore whether the presence or absence of dexamethasone may affect cell 
differentiation, adipogenesis, and gene expression ofBrn3b and PPARy. 
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I Seven 185.88 (±25.55) 11.70 (±0.111716) 
As shown in the table, the concentration and purity indicated high yield with 260/280 ratios 
from 1.66 up to 2.04. 
NanoDrop graphs: 
An example of a NanoDrop graph from the third experiment tube no.l of day zero 
representing a good quality and high concentration represented by the peak of RNA absorbing 
at 260nm wavelength see Figure 14. 
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Figure 14 a good NanoDrop graph 
An example of relatively low standard quality NanoDrop graph (Figure 15) from the third 
experiment tube no.5 of day three, showing an Ethanol contamination peak at about 230nm 
wavelength. 
RNA 
/ 
Figure 15 a low quality RNA NanoDrop graph 
RESULTS 
Morphological Changes of 3T3L-1 Cells 
The following images demonstrate morphological changes of 3T3L-1 Cells in different 
I groups in response to different media: 
0 
0 
Confluency of preadipocytes 
Primarily, cells were resurrected and proliferated; the following images (Figures 4A, 4B) 
show preadipocytes growing in a culture flask: 
Figure 4 preadipocytes nearly conOuent (A), preadipocytes 100% conOuent (8), high glucose 
preadipocyte media used. magnification 20X . 
Images have been taken for cells at all different days except day zero, since cells at day zero 
look the same as ordinary preadipocytes. 
A- Effect of high glucose medium without dexamethasone on differentiation of 
3T3L-l cells 
3T3-Ll cells at different time points of differentiation from preadipocytes to adipocytes using 
different magnification (5, 10 and 20X) were illustrated in figures 5-7. Figures clearly 
indicate well differentiation over time points studied and changes in cell morphology from 
fibroblast like spindle shape to fat laden round cells. 
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Day3 Day5 Day7 
Figure 5 cells of the first experiment. At day 3 after adding the high glucose differentiation media (A), at day 5 
(B), and at day7 (C), Maintenance media used without Dexamethasone, magnification 5X. 
Figure 6 cells of the first experiment. At day 3 after adding the high glucose differentiation media (A), at day 5 
(B), and at day7 (C), Maintenance media used without Dexamethasone, magnification 1 OX. 
Day3 
Figure 7 cells of the first experiment. At day 3 after adding the high glucose differentiation media (A), at day 5 
(B), and at day7 (C), Maintenance media used without Dexamethasone, magnification 20X. 
8- Effect of high glucose medium with dexamethasone on differentiation of 3T3L-1 
cells 
Cells shown in figures 8-10 represent 3T3-Ll cells at different time points of differentiation 
from preadipocytes to adipocytes. Figures clearly indicate well differentiation over days of 
the experiment. 
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Day3 DayS 
Figure 8 cells of the third experiment. At day 3 after adding the high glucose differentiation media (A), at dayS 
(B), and at day9 (C), Maintenance media used with Dexamethasone, magnification SX. 
Figure 9 cells of the third experiment. At dayS (A), and at day9 (B), Maintenance media used with 
Dexamethasone, magnification 1 OX. 
Figure 10 cells of the third experiment. At dayS (A), and at day9 (B), Maintenance media used with 
Dexamethasone, magnification 20X. 
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C- Effect of low glucose medium with dexamethasone on Differentiation of 3T3L-1 
cells 
Cells in figures 11-13 illustrate 3T3-Ll cells at different time points of the low glucose 
experiment. The figures clearly indicate poor and lack of differentiation over time points 
studied. 
Figure II cells of the fourth experiment. At day3 after adding low glucose differentiation media (A), at day5 (B), 
and at Day7 (C), Maintenance media used with Dexamethasone and low glucose, magnification 5X. 
Day3 Day7 
----..~l""'r"--... 
Figure 12 cells of the fourth experiment. At day3 (A), and at day7 (8), Maintenance media used with 
Dexamethasone and low glucose, magnification 1 OX. 
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Day 5 Day7 
Figure 13 undifferentiated preadipocytes of the fourth experiment at day 5 (A), with only one possibly 
differentiating cell in the middle of the image. At day7 (B), Maintenance media used with Dexamethasone and 
low glucose. 20X magnification. 
RNA Extraction Results 
Table (3) shows the mean RNA concentration and purity for each day from each experiment 
obtained by NanoDrop, data are shown as mean (± Standard Deviation): 
Table 3. Mean RNA concentration and purity 
Group Day Concentration ng/'11 260/280 
Zero 1567.5 (±658.76) 2.00 (±0.015986) 
First group 
Three 383.01 (±71.69) 1.92 (±0.008165) 
(High glucose, 
Five 377.03 (±68.21) 1.92 (±0.05647) 
without Dex.) 
Seven 299.1 (±36.98) 1.96 (±0.046188) 
Zero 264.6 (±294.69) 1.72 (±0.24683) 
Second group 
Three 94.03 (±44.54) 1.55 (±0.1 0976) 
(High glucose, with 
Five 128.26 (±50.19) 1.86 (±0.152394) 
Dex.) 
Nine 126.36 (±62.60) 1.79 (±0.109202) 
Third group Zero 272.06 (±130.78) 1.75 (±0.181177) 
(Low glucose, with Three 130.78 (±37.95) 1.66 (±0.1 027) 
Dex.) Five 139.31 (±40.95) I. 74 (±0.114078) 
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METHODOLOGY 
Materials 
Cells were purchased from Zen Bio Company, (Chapel Hill-Nelson Blvd., Suite 104, PO Box 
13888/ Research Triangle Park, NC 27709, USA). Cryopreserved 3T3-L1 preadipocytes were 
received in 2ml vial containing 0.5 million cells of passage 8, Cat# SP-L1-F, and media were 
purchased alongside the cells from the same company (Zen Bio). The media were: 3T3-L1 
Preadipocyte Media, Cat# PM-1-L-1 (contains 4.5g/L D-glucose, equals - 25 mM); 3T3-L1 
Adipocyte Maintenance Media, Cat# AM-1-L-1; 3T3-L 1 Adipocyte Maintenance Media 
without dexamethasone, Cat# AM-1-L-1-DF; 3T3-L1 Adipocyte Differentiation Medium, 
Cat# DM-2-L-1; and Cryopreservation Medium for 3T3-L1 cells, Cat# FM-1-L-1-100. All 
media except Preadipocyte Media, Cat# PM-1-L-1, contained 3.15g/L D-glucose, (equals -
17.5 mM). 
3T3-L1 Adipocyte Differentiation Medium containing low glucose (lg/L= - 5.5 mM), Cat# 
C0-5; and 3T3-L1 Adipocyte Medium containing low glucose (lg/L= - 5.5 mM) DMEM, 
Cat# C0-5 were also obtained from Zen Bio Company. 
Other materials and reagents used in this study were: Trypsin/ EDTA (TE) solution (1X), 
REF# R-001-100, was from Gibco (Life Technologies, UK). Phosphate Buffered Saline 
(PBS) pH 7.4 (1X), was from Gibco (Life Technologies, UK). TRizol Reagent Ambion RNA 
[REF #15596026] was purchased from Life Technologies USA. Chloroform HPLC grade, 
Code: C/4966/15, was purchased from Fisher Scientific. RNase free water was from 
PreAnalytiX/ Qiagen, # 1057099 Hilden, Germany. Agilent RNA 6000 Pico Kit was from 
Agilent Technologies, Waldbronn- Germany. High Capacity RNA-to-eDNA kit was 
purchased from Applied Biosystems PIN 4387406. TaqMan Gene Expression Master Mix 
(PIN 4369016); Pre-Developed TaqMan Assay Reagents, Mouse ACTB (20X) (Ref# 
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4352933E, UK); TaqMan® Gene Expression Assays, Ref# 00440945 (Mouse PP ARy 
primer); and TaqMan® Gene Expression Assays, Ref# Hs00960964_g1, PN4351372 (Mouse 
POU4F2/Bm3b primer), were all purchased from Applied Biosystems Foster, USA. 
All other materials used in this study were of high quality and purchased from Sigma (St. 
Louis, MO, USA) 
Ethical and Biosafety Approvals 
Qatar University institutional review board has exempted this study, exemption number: QU-
IRB 269-E/13; see Appendix II. Qatar university institutional Bio-safety committee has 
approved this study, approval number: QU-IBC 3113-14, see Appendix III. 
Cell Culture 
Cryopreserved 3T3L-1 preadipocytes Passage 8 were received and kept in -80°C. They were 
transported in liquid Nitrogen from Qatar University campus, biomedical research labs to 
Anti Doping Laboratory- Qatar (ADL-Q), where all work had been conducted. 3T3L-1 cells 
were resurrected before work by thawing them in a water bath at 37°C. Cells were washed in 
pre-warmed 5ml preadipocytes media (PM-1-L-1) in a 15ml tube, then centrifuged at 1000 
rpm for 2 minutes. Washing purpose was performed to get rid of all Dimethyl sulfoxide 
(DMSO) that was used in the cryopreserving media. After centrifugation, the supernatant was 
discarded and the cells were resuspended in 2.5 ml pre-warmed PM-1-L-1 media and were 
seeded in a small (25 CM3) culture flask containing 2.5ml warm PM-1-L-1 media and labeled 
as Passage Number 9 (P9). The cells were checked under the microscope (Leice Microscope 
DMI 3000 B, 5X magnification) to make sure that sufficient amount of cells had been 
transferred to the flask before placing it in the humidified incubator (37°C, 5% C02). 
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Figure 3 Nearly confluent cells. 20X maginification 
After 18 hours incubation, the 3T3-L1 
preadipocytes have adhered to the flask and 
started its division. Figure 3 to the left is 
showing cells nearly confluent. Cells were re-
fed by removing old media (without touching 
the surface containing the cells) and 
replacing it with fresh 7.0 ml pre-warmed PM-1-L-1 media. The media had been changed 
always in the next day of seeding to remove debris and any dead unstuck cells. 
Cell Passage 
Each time cells had to be used in an experiment, cells had to be taken off the plate in order to 
grow and multiply. Pre warmed Trypsin EDT A (TE) was used to peal cells off the plate, after 
removing the media and washing the cells with phosphate buffer saline (PBS) 5ml in case of 
using 75CM3 flask and 2.5 ml in case of using 25CM3 flask. Cells were incubated with TE for 
2 minutes at 37°C; after visualizing the cells under microscope and making sure they were 
dislodged, cells were mixed and placed in 15 ml tube. The flask was washed again with 5ml 
warm PM-1-L-1 to take any remaining cells and added them on top of the TE washed ones. 
The tube containing TE treated cells was then centrifuged at 1000 rpm for 5 minutes. The 
resulting supernatant was discarded, only small amount (- 0.5- 1 ml) was left to resuspend the 
cells. The cells pellet became ready to add PM-1 -L-1 warm media to reseed or count them. 
In case of freezing cells away, after treating cells with TE (the procedure described above), 
the cell pellet was resuspended in 0.5-1 ml warm cryopreserving media (amount depends on 
the number of cells); then 500fll of the cell suspension was placed in different 2ml 
cryopreserving tubes, which were stored straight in -80°C freezer. 
13 
Cell Count 
Cell count was performed routinely and before the differentiation procedure. Cell to cell 
contact may enhance differentiation, and by counting cells we ascertain cells in all wells start 
differentiation at the same time. When counting cells was required; cells were treated with 
TE (the way described before). Upon re-suspending cells with PM-1-L-1 media, a small 
amount was taken (- 20 f.J.l) and placed it on hemacytometer (Bright Line) and was covered 
with cover slip. The number of cells counted in the middle 25 squares was multiplied by 104 
per ml: 
For example: in one experiment 56 cells in the 25 middle squares was gotten, then: 
Cell Differentiation 
Four 6-well plates for each differentiation experiment were used. All four plates were labeled 
and 1.5 warm PM-1-L-1 media was placed in each of their 6 wells. The same quantity of cells 
was seeded in each well. Then, the plates were kept in 3 7°C, 5% C02 incubator and in the 
next day PM-1-L-1 media was changed. When the cells became - 100% confluent, the PM-1-
L-1 media was replaced with warm differentiation media DM-2-L1 (3.15 giL glucose), 1.5 ml 
I well; and the cells in these plates were labeled day zero (DO). Thereafter, one of these plates 
was taken at day zero and its media was removed and cells were washed with 0.5 ml TRizol 
reagent and placed in a microcentrifuge tube labeled with number, date, and day number (a 
tube for each well). Another 0.5 ml TRizol was added in each well to wash any cell remnants 
and again transferred to the corresponding tube. Tubes were then kept in -80°C until initiation 
of RNA extraction. 
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For differentiation of the cells, they were exposed to the differentiation media for certain 
number of days followed by the maintenance medium, as shown in details in the next 
paragraph. 
For the other plates differentiation media was left on the cells for three days; after that, it was 
replaced with Adipocyte Maintenance media AM-1-L-1; and these plates were labeled day 
three (D3). One of the plates labeled day three (D3) was imaged under the microscope (Leice 
Microscope DMI 3000 B, 5X, 1 OX, and 20X magnification). Following that, its media was 
removed and the cells were harvested in TRizol reagent the way described before. Two days 
later, Adipocyte Maintenance media AM-1-L-1 was again refreshed in the remaining plate, 
which was labeled day 5 (D5) and processed exactly as described for day 0 and day3. The 
other plate was processed exactly as described for day 0 and day3. Two more days, on day 
seven (D7), the remaining plate was taken out, and processed exactly as described for day 0, 
day3 and day 5 and the cells treated with TRizol reagent and kept in -80 °C waiting for RNA 
extraction. 
The Study Groups 
There were three groups in this study based upon the contents of the Differentiation and 
Adipocyte Maintenance media. Each group was repeated two times. 
A- 3T3L-1 in high glucose Adipocyte Maintenance media without dexamethasone 
It was performed exactly as described above in the previous paragraph, but the only difference 
that on day three, Adipocyte Maintenance media was used without dexamethasone (AM-1-L-
1-DF) and continued thereafter for day 5 and day 7. 
B- 3T3L-1 in high glucose Adipocyte Maintenance media with dexamethasone 
In the third differentiation experiment, on day three, the Adipocyte Maintenance media AM-
1-L-1 was used (already containing dexamethasone) and our experiment was performed 
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exactly as described in the previous paragraph. In addition, the cells of the last plate were kept 
for additional time until day nine (D9). 
C- 3T3L-1 in low glucose (lg/L) Adipocyte Maintenance media with dexamethasone 
In this experiment, differentiation media with low glucose was used (1g/L) C0-5 on day zero 
(DO), and Adipocyte Maintenance media with low glucose DMEM C0-5 (already contained 
dexamethasone) on day three (D3). the cells were kept until day seven (D7) only; and TRizol 
reagent was added to the cells by pipetting up and down, and then the cells were kept at -80° 
C for further RNA extraction. 
Total RNA Extraction 
Total RNA was extracted from the cells that were preserved in TRizol reagent at -80° C, 
according to the protocol provided by the manufacturer (REF #15596026, Ambion RNA by 
Life Technologies, USA). The tubes containing cell extract in 1ml TRizol each were taken 
out of freezer and left to be thawed. Then, 200J.1l chloroform was added to each tube; then the 
tubes were shaken and incubated in room temperature for 2-3 minutes. After that, the tubes 
were centrifuged for 15 minutes at 13000 rpm and 4°C, whereas the mixture separated into a 
lower red phenol-chloroform phase, an interphase, and a colorless upper aqueous phase. The 
colorless upper phase contained RNA, which was harvested and placed in a clean labeled 
microcentrifuge tubes. 500J.1l of 100% isopropanol was added on each tube and incubated in -
20°C for 1 hour or overnight. After that, the tubes were centrifuged for 1 0 minutes at 13000 
rpm and 4°C. RNA formed a pellet on the bottom and side of the tubes. The supernatant was 
discarded without disturbing the pellet. 1ml 70% Ethanol was then added on each tube for 
washing and mixed slightly. Again, the tubes were centrifuged for 5 minutes at 13000 rpm at 
4°C. The supernatant was removed completely without disturbing the pellet, and then left to 
air dry. RNA pellet was then resuspended in 30J.Ll RNase- free water and mixed well then 
16 
placed in heat block at 55°C for 10 minutes. After that, the tubes were placed on ice and RNA 
concentration was measured using NanoDrop. 
RNA Quality Estimation 
Apart from measuring RNA samples by NanoDrop, some randomly chosen samples were 
analyzed using Agilent RNA Bioanalyzer to check its quality and purity. The Procedures were 
followed according to the Agilent RNA 6000 Pico Kit Quick Start Guide provided by the 
company. RNA gel matrix was prepared first by pipetting 550 J .tl into a spin filter (provided 
with the kit); and centrifuged at 1500 g for 10 minutes at room temperature. Out of the filtered 
550 J •.tl, only 65 Jll was needed in an RNase-free microcentrifuge tube. 1 Jll of RNA dye 
concentrate was vortexed for 10 seconds, after equilibrated to room temperature for 30 
minutes, then spun down and added to the filtered 65 Jll of RNA gel matrix. The tube then 
was vortexed and centrifuged at 13000g for 10 minutes at room temperature. 9 Jll of the gel-
dye mix was added in the third "G" marked well of the chip. The plunger was set at 1 ml 
position and chip priming station was closed. The plunger was pressed until held by the clip, 
and then released after waiting for exactly 30 seconds. After waiting another 5 seconds, the 
0 plunger was repositioned to 1ml and the chip priming station was opened for adding another 9 
Jll of the gel-dye mix on each of the two "G" labeled wells. 9 Jll of the RNA conditioning 
solution was pi petted into the well marked CS. Then, 5J.1I of RNA marker was added on all 11 
remaining wells plus the ladder well. following that, 1 Jll of the pre-heated (70°C for 2 min) 
RNA samples was pipetted each into its corresponding well, along with 1 Jll of the heat 
denatured ladder in the well marked ladder. The chip then was vortexed in the special chip 
vortexer for 1 min at 2400 rpm; then chip was placed in Agilent 2100 Bioanalyzer instrument. 
Run took around 20-30 minutes to finish. 
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eDNA Synthesis 
eDNA was prepared according to the manufacturer of High Capacity RNA-to-eDNA kit (PIN 
4387406, Applied Biosystems, USA). 2 tubes from each day of the four experiments (of the 
three groups) were selected according to RNA quality and concentration. The reaction mix 
was prepared then distributed on all labeled PCR tubes. After that, RNA and water were 
added with different quantities each according to RNA concentration. Generally, the eDNA 
synthesis mixture had the following components, as shown in the following table: 
Table 1. eDNA synthesis mixture 
Component Volume/Reaction (p.d) 
2X RT Buffer 10.0 
20X Enzyme Mix 1.0 
RNA Sample 1-9 (according to concentration) 
Nuclease-free H20 1-8 (according to RNA sample volume) 
Total per Reaction 20 
The tubes were caped and mixed by vortex then spun down before placing them in thermo-
cycler. Reverse transcription reaction was performed according to manufacturer's protocol: 
37°C for 60 minutes followed by 95°C for 5 minutes then hold at 4°C. eDNA tubes were kept 
in the freezer at -20°C. 
For details about calculations done for the chosen 32 samples see Appendix I 
Real Time PCR 
For gene expression experiments, Applied Biosystems real-time quantitative PCR ViiA 7 
instrument was used. TaqMan Gene Expression Master Mix (PIN 4369016) from Applied 
Biosystems was used as well. 
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After preparing all eDNA samples and unifying their concentrations to the recommended 200 
ng/J..Ll (as illustrated in Appendix I), the PCR reaction mix was prepared. A tube of PCR 
reaction mixture enough for 32 samples was prepared each time for beta-actin and PPARy 
genes. One negative control well containing water instead of eDNA was prepared as well. 
The reaction mixture contained the following components as shown in the following table: 
Table 2. qPCR mixture for P-actio and PP ARy or Brn3b 
Content Amount per sample P-actin for 34 samples PPARy/Bm3b for 34 samples 
Master Mix 10 J..Ll 340 J..Ll 340 J..Ll 
0 Primer 1 J..Ll 34 J..Ll (p-actin primer) 34 J..Ll (PPARy primer) RNA free H20 8 J..Ll 272 J..Ll 272 J..Ll 
eDNA (200ng) 1 J..Ll - -
-
Total 20 fll 646 fll 646 fll 
19 J..Ll from each mixture were distributed in the corresponding wells in the optical 96-well 
plate, and then 1 J..Ll from each eDNA sample was added. The plate was then sealed with 
adhesive cover and centrifuged, and then was placed in the real-time PCR instrument. 
Another mixture was performed exactly the same for Bm3b and P-actin as endogenous 
control. 
Cycle threshold (Cr) defined as the cycle number at which a significant increase in the 
fluorescence signal compared to background emission is first detected. Calculating Cr values 
for each sample was performed to quantify unknown samples. 8Cr defined for each sample 
by subtracting the P-actin gene Cr from each selected gene Cr. Relative gene expression was 
calculated by the 2-MCT methods, i.e. as the negative exponential power of2 of each sample's 
8Cr minus the 8Cr of a reference sample, which kept constant throughout experiments. 
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Statistical Data Analysis 
Data were explored for outliers, skewness, and normality using Shapiro-Wilk test and log 
transformed when necessary for the statistical analysis, if normality assumption was violated, 
and thereafter back transformed for data presentation. 
Continuous data are expressed as median and inter-quartile range [25%- 75%] with standard 
deviation, as shown in table 9. 
Each experiment was independently repeated at least two times. All values in the figures are 
expressed as median and inter-quartile range and/or mean with standard deviation. To 
determine statistical significance within each group exposed for the same medium, the values 
were compared versus day 0 (as a control or reference day) with paired Student's t -tests. To 
determine the statistical significance between the different groups exposed for different media 
at days 3, 5 and 7, unpaired Student's t -tests were used for this comparison. All statistical 
analyses were performed using the SPSS program for Windows (version 21 statistical 
software; Texas instruments, IL, USA), and Microsoft excel (version 2010 stat software) were 
used for graphs. Two-tailed P value < 0.05 is statistically significant. 
Work Scheme 
First, second and third groups are shown in the following scheme. All were repeated twice. 
First experiment (group): High glucose without dexamethasone (HG-DEX). 
Second (group): High glucose with dexamethasone (HG+DEX). 
Third (group): Low glucose with dexamethasone (LG + DEX). 
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First Second Third 
Cell culture Cell culture Cell culture 
High glucose differentiation High glucose differentiation low glucose differentiation 
media (3.15g/L) media (3.15g/L) media (1 g/L) 
Maintenance media without Maintenance media with Maintenance media low 
Dexamethasone Dexamethasone glucose with Dexamethasone 
RNA extracted at day 0,3,5, & RNA extracted at day 0,3,5, & RNA extracted at day 0,3,5, & 
7; each plate had 6 wells 9; each plate had 6 wells 7; each plate had 6 wells 
eDNA synthesized eDNA synthesized eDNA synthesized 
• • • 
Gene expression evaluated Gene expression evaluated Gene expression evaluated 
0 
0 
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Agilent RNA Bioanalyzer Results 
RNA quality and concentration estimation by NanoDrop is not sufficient; therefore, RNA 
samples were run on Agilent 21 00 Bioanalyzer. Some samples gave a good yield and pure 
RNA, while others were of poor quality. Figure 16 shows an example of the good (16.A) and 
a poor (16.8) quality RNA. 
A B 
509 6 day o 
[FU] (FU] 
300 200 
200 
100 
100 
0 
-
0 ~ 
-
-ntj 25 200 1000 4000 [nt] 
Overall Results for sample 10 : 509 Overall Results for Qmple 3 : ~ 
RNA Area: 2,481.0 RNA Area: 1,635.7 
RNA Conc.Mir.ltian: 15,922 P!lll'l RNA Ccnu:ntratlon: 11,418 PU/1'1 
rRNA Ratio [2Bs /185]: 1.3 •RNA Rat;o [2Bs / 18s): 1.1 
RNA lntl!!J1ty Ntmber {RIN): 7.8 {8.02.08) RNAint ·ty N (Ritl): 2.6 (8.02.08) 
Re5ult ~ng Color. c::::::I R RllgOing Color. I::::::J 
Ri.'sUt A..Sng Labd: RJN; 7.80 Reoult Fbgging Label: RlN: 2.60 
Fragment table for sample 10 : ~ Fragment table for sample 3 : ~ 
Name Start Size [nt] End Size [nt] Area % of total Area Name start Size [nt) End Size [nt) Area "'- of total Area 
18S 1,627 1,831 3401 13.7 185 1,76oC 2,305 11 .2 0.7 
28S 3,059 3,814 4515 18.2 2tS 3,375 4 083 12.5 0 8 
Figure 16. Agilent Bioanalyzer RNA quality estimation results; A good quality RNA (A), and a poor quality 
RNA (B). RNA area represents the total RNA area. RNA concentration is calculated from the area. rRNA ratio is 
the ribosomal RNA ratio of28s/ 18s. RIN number better be above 6. 
Gene Expression Results 
A- PPARy gene expression in different groups (Figures 17-21) 
PCR was performed on 2 tubes of each time point for the 3 studied groups and repeated twice. 
Cycle Threshold (Cr) values for PPARy gene were obtained and mean Cr values were 
calculated; and then referring first to the Cr values for endogenous control P-actio then 
referring to day zero tube of each experiment ~~Cr values were calculated. Fold differences 
were then obtained by getting (2-Mcr); Delta Cr = Cr PPARy - Cr p.actin I Delta Delta Cr = ~Cr 
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sample# - ~Cr oayo. Fold change range was established by subtracting or adding standard 
deviation to (2-Mcr) .In the following figures, bars are showing fold difference ± standard 
deviation ofPPARy expression in different days in the three groups. 
PPARy mRNA expression in response to HG-DXmedia: 
3T3-L1 cells exposed to high glucose without dexamethasone showed progressive and 
significant increase in mRNA expression ofPP ARy as shown in figure 17 and table 4. PPARy 
0 expression increased about 6. 7 folds from day 0 to day 3; and from day 0 to day 5 by 18.1 
0 
0 
0 
folds; and increased from day 0 to day 7 by 19.8 folds. 
Data were explored for normality distribution by histogram and Sharipo-Wilk test for normal 
distribution and accept normality; hence, paired sample t-test was used to compare the gene 
expression in different days of adipogenesis within each treatment group versus day 0, results 
obtained for high glucose without dexamethasone were illustrated in table 4. 
Table (4) is displaying the statistical details of fold increase for the high glucose without 
dexamethasone group with P- values calculated using Paired T -test compared to dayO of the 
same group. 
Table 4. Mean Cr values for PPARy and JJ-actin in 3T3-Ll cells with calculations of 
ACr, AACr, fold change± standard deviation, and P values compared to dayO (as a 
control) for high glucose without dexamethasone group 
Fold difference 
ACr AACr(ACr P-value 
PPARy JJ-actin in PPARy 
Day (PPARy- day#-ACr compared 
mean Cr mean Cr relative to JJ-
JJ-actin) dayO) to dayO 
actin 
DayO 28.14±0.56 19.60±0.53 8.54±0.78 0.00±0.78 1.0 (0.5-1.7) -
Day3 27.34±0.57 21.56±0.25 5.78±0.62 -2.75±0.62 6.7 (4.3-10.4) 0.0103 
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DayS 25.59±0.45 21.23±0.19 4.36±0.49 -4.17±0.49 18.1 (12.8-25.5) 0.0007 
Day7 24.82±0.31 20.60±0.36 4.22±0.47 -4.31±0.47 19.8 (14.2-27.7) 0.0014 
Data illustrated in figure 17 is showing column graph of the values displayed in table 4; fold 
change of PP ARy mRNA expression relative to P-actin endogenous gene are shown with 
error bars representing standard deviation. The figure shows the progressive increase in 
PP ARy expression during adipogenesis. 
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Figure 17. Column graph of PPARy mRNA expression among the days of differentiation for high glucose 
without dexamethasone group, represented by the fold change (2·MCT) ±: SD. (n- 4 for each day). Two 
tailed p value is significant at * P<0.05 vs. adipocytes at day 0 as a control. 
P P ARy mRNA expression in response to HG+ DX media: 
Similar observations were observed for 3T3-L1 cells that were exposed to high glucose media 
with dexamethasone, whereas progressive increase in mRNA expression of PPARy was 
noticed as shown in figure 18 and table 5. The increase in the PPARy expression from day 0 
to day 3 was 10.7 folds; and from day 0 to day 5 was 17.2 folds; and from day 0 to day 9 by 
17.4 folds. Table 5 illustrates the statistical details of fold increase for the high glucose with 
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dexamethasone group and P-values obtained by Paired T -test compared to dayO of the same 
group. 
Table 5. Mean CT values for PP ARy and P-actio in 3T3-Ll cells with calculations of 
ACT, AACT, fold change± standard deviation, and P values compared to dayO for high 
glucose with dexamethasone group 
Fold difference 
ACT AACT(ACT P-value 
PPARy P-actio inPPARy 
Day (PPARy- day#-ACT compared 
meanCT mean CT relative to P-
P-actio) dayO) to dayO 
actin 
DayO 27.66±0.24 18.81±0.36 8.85±0.43 0.00±0.43 1.0 (0.7-1.3) 
-
Day3 28.71±1.25 23.29±1.33 5.41±1.83 -3.43±1.83 10.7(3.0-38.5) 0.0006 
Day5 25.65±0.40 20.90±0.40 4.74±0.56 -4.10±0.56 17.2(11.6-25.5) 0.033 
Day9 25.77±0.24 21.05±0.32 4.72±0.40 -4.12±0.40 17.4 (13.1-22.9) 0.0002 
Data shown in figure 18 represent column graph of the values displayed in table 5; fold 
0 change of PPARy mRNA expression relative to P-actin endogenous gene are shown with 
error bars representing standard deviation. The figure shows the progressive increase in 
PPARy expression during adipogenesis with a noticeable high increase in day3. 
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Figure 18. Column graph of PPARy mRNA expression among the days of differentiation for high glucose 
with dexamethasone group, represented by the fold change (2·MCT) ± SD. (n=4 for each day). * P<0.05 vs. 
adipocytes at day 0 as a control. 
PPARy mRNA expression in response to LG+DX media: 
3T3-Ll cells grown in low glucose media with dexamethasone exhibited limited mRNA gene 
expression of PP ARy as shown in figure 19 and table 6. There were slight increase in PP ARy 
expression; from day 0 to day 3 increased by 2.3 folds; and increased from day 0 to day 5 by 
3.7 folds; and from day 0 to day 7 increased only by 3.3 folds. Table (6) reveals the slight 
statistical change of PPARy expression for the low glucose with dexamethasone group along 
with P-values calculated using Paired T -test compared to day 0 of the same group. 
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Table 6. Mean CT values for PP ARy and P-actio in 3T3-Ll cells with calculations of 
ACT, AACT, fold change± standard deviation, and P values compared to dayO for low 
glucose with dexamethasone group 
Day PPARy P-actio ACT AACT (ACT Fold 
mean CT mean CT (PPARy- day# - ACT difference in P-value 
P-actio) dayO) PPARy compared to 
relative to P- dayO 
actin 
DayO 28.19±0.74 20.26±0.85 8.64±1.13 0.00±1.13 1.0 (0.4-2.1) -
Day3 29.55±0.40 22.10±0.32 7.44±0.51 -1.20±0.51 2.3 (1.6-3.2) 0.0798 
Day5 28.04±0.49 21.30±0.42 6.73±0.65 -1.91±0.65 3.7 (2.3-5.9) 0.0053 
Day7 28.46±0.27 21.56±0.22 6.89±0.35 -1.74±0.35 3.3 (2.6-4.2) 0.0126 
The graph shown in figure 19 presents the values displayed in table 8; fold change of PP ARy 
mRNA expression relative to P-actin endogenous gene are shown with error bars representing 
standard deviation. The figure shows the slight increase in PP ARy expression during 
adipogenesis with low glucose medium (1g/L). 
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Figure 19. Histogram of PPARy mRNA expression in low glucose with dexamethasone experiment, 
represented by the fold change (2-.ucT) ± SD. (n=4 for each day). * P<O.OS vs. adipocytes at day 0 as a 
control. 3T3Ll cells were treated with low glucose with dexamethasone as indicated in methods section. 
Total RNA extracted as indicated at the time points and reverse transcribed using qPCR. 
P P ARy mRNA expression in response to HG+ DX versus LG+ DX media: 
A comparison of PPARy mRNA expression between high glucose (3.15g/L) and low glucose 
(l g/L) groups both with dexamethasone is shown in figure 20. Statistical analysis 
demonstrated significant difference in the PP ARy gene expression between high glucose 
compared to low glucose at different time points. Table (7) demonstrates P values for days 3, 
5, and 7/9 between high glucose and low glucose groups. 
Table 7. P-values for the comparison between high glucose and low glucose both with 
dexamethasone groups at different days obtained by Paired T -test 
Paired T- test 
HG+DEX vs. LG+DEX 
Day P value Significance 
day3 0.0001 Significant 
day 5 0.0209 Significant 
day7 0.0001 Significant 
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The higher PPARy gene expression in high glucose group compared to low glucose group is 
represented in figure 20. Data are represented by fold change (2·MCT) 
HG+DX vs. LG+DX 
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Figure 20 a comparison of relative PPARy mRNA expression (fold change 2-MCT) in response to high 
(blue) versus low glucose (red) media with dexamethasone. Data are presented as mean with SD of PPARy 
in different days (n=4 for each day in each group). * P<0.05 is significantly different between exact days 
(3, 5, and 7/9) in two groups, while day 0 is used as control for both groups after normalization and 
calibration as a reference. 
PPARy mRNA expression in response to high glucose media in the presence and absence of 
dexamethasone 
Statistical analysis demonstrated significant difference in the PP ARy gene expression between 
high glucose groups using dexamethasone or without using dexamethasone only at day3 of 
the experiment as shown in figure 21 . Relative PP ARy gene expression at day3 of the high 
glucose with dexamethasone was significantly higher than PP ARy gene expression in the high 
glucose without dexamethasone group at the same day. No significant difference has been 
detected in days 5 and 7/9 between groups with dexamethasone and without dexamethasone. 
Table (8) demonstrates P values for days 3, 5, and 7/9 between high glucose groups using or 
not using dexamethasone. 
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Table 8. P-values for the comparison between high glucose with and without I dexamethasone groups at different days obtained by Unpaired T -test 
0 
0 
Unpaired T- test 
HG with DEX vs. HG without DEX 
Day P value Significance 
day 3 0.0024 significant 
day 5 0.0918 Not significant 
day 7/9 0.8589 Not significant 
The difference in PPARy gene expression between high glucose group with dexamethasone 
(red) and without dexamethasone (blue) at different time points is illustrated in figure 21. 
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Figure 21 a comparison of PPARy mRNA expression fold change (2-McT) in response to high glucose 
media with (red) and without dexamethasone (blue). Data are presented as mean of PPARy in different 
days (n=4 for each day in each group). * P<O.OS is significantly different between the exact day of 
differentiation (3) in the two groups, while day 0 is used as control for both groups after normalization 
and calibration to day 0 for each group as a reference. 
PPARy gene expression in all studied groups 
In another way of representing the results in one block, figure 22 show the three groups high 
glucose without dexamethasone, high glucose with dexamethasone, and low glucose with 
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dexamethasone in single view. Table 9 illustrates the numerical details of the median and 
inter-quartiles (25%-75%) with standard deviation for the three studied groups. Figure 22 
represents fold change of all groups, where rectangles represent inter-quartiles (25%-75%) 
with median at 50% and error bars represent SD of the median. 
Table 9. A comparison between the three groups in median and inter-quartiles (25%-
75%)with SD 
Day& group Median 25-75 p Standard Deviation 
DayO-HG-Dex 0.978 0.74-1.00 0.16 
Day3-HG-Dex 5.820 4.80-7.96 1.69 
Day5-HG-Dex 16.809 9.92-26.85 8.85 
Day7-HG-Dex 16.898 11.47-30.58 10.52 
DayO-HG+Dex 1.074 0.96-1. 16 0. 10 
Day3-HG+Dex 11.119 I 0.65-12.90 1.31 
Day5-HG+Dex 18.397 17.76-18.91 0.61 
Day9-HG+Dex 18.648 17.07-20.14 1.66 
DayO-LG+Dex 1.288 0.69-2.07 0.71 
Day3-LG+Dex 2.770 2.36-3.25 0.46 
Day5-LG+Dex 4.538 4.21-4.83 0.33 
Day7-LG+Dex 4.030 3.47-4.73 0.66 
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Figure 22 Comparison of the three treatment groups showing PPARy gene expression expressed by fold 
change (2-McT). Data presented as median (interquartile range), with error bars representing SD. 
0 Figure 23 shows amplification plot of PP ARy versus P-actin. 
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Figure 23 amplification plot of PPARy gene (blue) versus p-actin (red). 
Of note, the housekeeping gene P-actin is used as control gene in our study showed consistent 
results in response to different media at different time points of adipogenesis without any 
significant or marked changes in expression. 
B- Brn3b gene expression 
PCR was also performed for the same samples used in our study, for PPRA gamma gene 
expression from different groups, for Brn3b along with P-actin gene as endogenous control. 
No amplification of Brn3b mRNA gene expression was detected in all experiments (for the 
three different groups) and in all time points (days 0,3 ,5,7 or 9) as shown in figure 24. No 
amplification ofBrn3b gene was observed between preadipocytes or adipocytes. 
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Figure 24 amplification plot of Brn3b gene (blue) versus P-actio (red). No amplification was seen in 
Brn3b. 
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DISCUSSION 
As obesity is spreading and gammg more attention, studies focusing on understanding 
mechanisms leading to obesity are being conducted. In this study, 3T3-Ll preadipocytes were 
successfully resurrected and grown in different glucose concentrations in the presence of 
insulin, as well with and without dexamethasone; intended for studying the expression of 
Bm3b transcription factor and its impact during adipogenesis compared with the well-known 
0 transcription factor PPARy. Three groups have been studied; in the first group cells were 
treated with high glucose media without dexamethasone, in the second group cells were 
treated with high glucose media with dexamethasone, and in the third group cells were treated 
with low glucose media with dexamethasone. The cell extract were obtained at days 0, 3, 5, 7 
and/or 9 and the gene expression at these days were evaluated for the expression ofBm3b and 
PP AR gamma by qPCR. The major finding of this study is that neither preadipocytes nor 
adipocytes at different points of differentiation with perturbations of glucose and 
dexamethasone show or demonstrate expression of Bm3b transcription factors at the mRNA 
level, while PPARy expression was expressed in preadipocytes as well as adipocytes under 
these conditions. The implications of this finding are discussed in the following paragraphs. 
Bm3b is known to be expressed abundantly in nervous tissue (Lillycrop et al, 1992), and 
other tissues such as retina (Wang et al., 2000), breast cells (Ounzain et al, 2011), testis 
(Budhram-Mahadeo et al, 2001), and peripheral blood cells (Niculescu et al, 2007), but there 
is no currently available published data regarding Bm3b expression in preadipocytes and 
adipocytes of the adipose tissue. The current data of this study revealed that Bm3b 
transcription factor is not expressed in the preadipocytes or into the mature adipocytes after 
differentiation whether in normal media or even with perturbations of glucose and 
dexamethasone in the growth differentiation and maintenance media used. To the best of our 
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knowledge, this is first study to look for Bm3b expression in preadipocytes and adipocytes in 
3T3-Ll murine cell model. These results correlate well with a parallel-unpublished study (Ms. 
Moza Alkwari, Dr. Vidya and Dr. Nasser) that was conducted on human adipose tissue of 
obese subjects. The unpublished study revealed that Bm3b was not expressed in isolated 
human adipocytes, but only expressed at the mRNA level in the stromal vascular cells 
obtained from the same subject particularly in subcutaneous and omental adipose depots. 
Therefore, the Bm3b expression that has been shown in stromal vascular fraction of the 
human adipose tissue probably originates from non-adipocytic lineage cells such as 
hematopoietic, endothelial, and stromal cells. These data are in agreement with our findings 
that neither preadipocytes nor mature adipocytes express Bm3b. Such findings need to be 
further investigated and confirmed by cellular and molecular experiments. 
Our results demonstrate that in glucose rich media (high glucose, 3.15 g/L), 3T3-Ll 
preadipocytes started to differentiate, compared with cells exposed to low glucose media 
(lg/L) that has been shown by morphological change at different days. When cells are left to 
grow in glucose rich media (high glucose, 3.15 giL), they started to differentiate. Cells 
differentiation started to be noticed at day three, which also can be confirmed by the gradual 
increment of the adipogenic gene expression PPARy. Later, at day five and day seven or nine, 
differentiated cells can be distinguished easily in the images by their intra-cellular fat 
droplets. The morphological results were further correlated with the significant increase of 
PPARy gene expression by many folds. Noticeably, cells grown in low glucose media (lg/L) 
were arrested and failed to differentiate, as confirmed by the lack of lipid accumulation in the 
cells and the limited changes in the adipogenic PP ARy gene expression. Obviously, results 
obtained point to the necessity of high glucose concentration to facilitate cells to differentiate. 
Glucose is an important nutrient and is important factor for differentiation of preadipocytes 
and adipogenesis (Aguiari eta/., 2008) (Yue eta/., 2010). Strong association ofPPARy with 
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adipogenesis and differentiation of preadipocytes into adipocytes was observed in this study 
as well as previous reports in literature (Schoonjans et a/., 1996) (Spiegelman et a/., 1997) 
(Spiegelman, 1998). However, dexamethasone seemed to exert its effect on cells 
differentiation and PP ARy expression at only the early stage of differentiation. As shown in 
the current results, PPARy expression at day3 in the group of high glucose with 
dexamethasone had higher fold change than that of the high glucose without dexamethasone 
group. Such findings are in parallel with the previous published data that point to the role of 
dexamethasone or glucocorticoids in adipogenesis. Several published reports indicated that 
dexamethasone stimulate C/EBP transcription factors family early during differentiation that 
in turn stimulates PP ARy expression. At later stage, CIEBPP and CIEBP~ expression 
decreases while CIEBPa is induced by PPARy (Ali eta/., 2013) (MacDougald & Mandrup, 
2002) (Wu, Puigserver & Spiegelman, 1999). In addition, the morphology of 3T3-L1 cells 
that have been grown with or without dexamethasone differentiated well and looked similar 
under microscope. Although graphs for PP ARy mRNA expression in cells grown with or 
without dexamethasone looked different, statistically there was no significant difference at the 
later stages, only at day 3 (early stage) dexamethasone induced PPARy mRNA expression and 
accelerate the adipogenesis, consistent with some previous studies (Hamm eta/., 1999) (Lai et 
a/., 1982). 
This study has several limitations; first only one cell type (3T3-L1) was used in this study. 
Second, Since Brn3b was found not to be expressed in preadipocytes, other known Brn3b 
expressing cells needed to be included as positive control. However, all other quality control 
measures have been taken, such as negative blank control and RNA quality check. 
In summary, Brn3b transcription factor was not expressed in adipocytes or their precursors 
preadipocytes. Glucose concentration is a significant factor in adipogenesis. PPARy is indeed 
an adipogenesis associated transcription factor. The presence of dexamethasone stimulated 
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adipocytes differentiation and the expression of PPARy at early stage, probably accompanied 
by the actions of other PP ARy activating transcription factors (Wu eta/., 1996). 
The findings of this study open up for many other studies and much further work to be done. 
Bm3b needs to be studied in different cell types and compared to a known Bm3b expressing 
type. Moreover, Bm3b at the level of protein and post transcriptional and translational change 
require examination. 
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CONCLUSION 
Adipogenesis was examined successfully in this study using the 3T3-Ll cell line. Media 
containing high glucose concentration was confirmed to be a crucial factor in adipogenesis, 
along with other factors such as dexamethasone, which were found to stimulate adipogenesis 
especially at early stage. As expected, PPARy gene expression was elevated during 
preadipocytes differentiation into adipocytes. On the contrary, mRNA of a novel transcription 
0 factor Bm3b was not detected in 3T3-Ll preadipocytes or in their differentiated adipocytes. 
0 
0 
Further studies are needed with other adipose cell lines and in vivo studies to determine the 
presence /absence of Bm3b expression. The effect of Bm3b, originating from other cell types 
within the adipose tissue need to be investigated in the future. 
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APPENDICES 
Appendix I 
The following table demonstrates the chosen 32 samples and the calculations of eDNA 
synthesis and dilution to 200ng/J.ll in preparation for PCR, 1 J.ll from each synthesized eDNA 
sample was mixed with the amount of water shown in the table: 
Sample ID Concentration Quantity of Final Water for dilution 
RNA concentration to 200 nglp.d 
D IDO-l - 1000 ng/J.ll 1.5 J.ll 1500 ng/J.ll 6.5 J.ll 
3D0-1 - 1 000 ng/ J.ll 1.5 J.ll 1500 ng/J.ll 6.5 J.ll 
··- -, 
4D3-1 538.6 ng/J.ll 4 J.ll 2154.4 ng/J.ll 9.7 J.ll 
-
6D3-1 353.5 ng/J.ll 6 J.ll 2121 ng/J.ll 9.6 J.ll 
. 
2D5-1 499.5 ng/J.ll 4 J.ll 1998 ng/J.ll 8.99 J.ll 
SDS-1 433.3 ng/J.ll 4 J.ll 1733.2 ng/J.ll 8.66 J.ll 
4D7-1 305.3 ng/J.ll 6 J.ll 1831.8 ng/J.ll 8 J.ll 
5D7-1 265.7 ng/J.ll 7 J.ll 1859.9 ng/J.ll 8.3 J.ll 
3D0-2 505 ng/J.ll 4 J.ll 2020 ng/J.ll 9 J.ll 
SD0-2 490 ng/J.ll 4 J.ll 1960 ng/J.ll 8.8 J.ll 
3D3-2 209.8 ng/J.ll 9 J!l 1888.2 ng/J.ll 8.4 J.ll 
6D3-2 96.2 ng/J.ll 9 J.ll 865.8 ng/J.ll 3.3 J.ll 
lDS-2 256.4 ng/J.ll 8 J.ll 2051.2 ng/J.ll 9 J.ll 
3D 5-2 272.6 ng/J.ll 7 J.ll 1908.2 ng/J.ll 8.5 J.ll 
2D7-2 274.9 ng/J.ll 7 J.ll 1924.3 ng/J.ll 8.5 J.ll 
4D7-2 262.4 ng/J.ll 7 J.ll 1836.8 ng/J.ll 8 J.ll 
53 
-·- ----- ---------- - -
lD0-3 634.8 ng/tJl 3 Ill 1904.4 ng/tJl 8.5 Ill 
I - ··-6D0-3 723.7 ng/tJl 2.5 Ill 1809 ng/lll 8 Ill 
--
5D3-3 149.9 ng/tJl 9 Ill 1349.1 ng/tJl 5.7 Ill 
--------
6D3-3 142.8 ng/tJl 9 Ill 1285.2 ng/tJl 5.4 Ill 
- ·- --- ··-
2D5-3 147.7 ng/tJl 9 Ill 1329.3 ng/lll 5.6 Ill 
5D5-3 208 ng/tJl 9 Ill 1872 ng/lll 8.3 Ill 
- . 
4D9-3 152.9 ng/tJl 9 Ill 1376 ng/tJl 5.8 Ill 
5D9-3 223.2 ng/tJl 9 Ill 2008.8 ng/tJl 9 Ill 
-
4D0-4 348.6 ng/tJl 6 Ill 2091.6 ng/lll 9.4 Ill 
-
6D0-4 357.4 ng/tJl 6 Ill 2144.4 ng/tJl 9.7 Ill 
1D3-4 172 ng/tJl 9 Ill 1548 ng/tJl 6.7 Ill 
4D3-4 179 ng/tJl 9 Ill 1611 ng/tJl 7 Ill 
5D5-4 175 ng/tJl 9 Ill 1575 ng/lll 6.8 Ill 
6D5-4 198 ng/tJl 9 Ill 1782 ng/tJl 7.9 Ill 
2D7-4 114 ng/tJl 9 Ill 1026 ng/lll 4.1 Ill 
6D7-4 123 ng/tJl 9 Ill 1107 ng/tJl 4.5 Ill 
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QA1AA UNIVU5 '1'Y 
Qatar University Institutional Review Board 
QU-IRB 
Nasser Ri~ 
Department of Health Sciences 
College or Arts and Science& 
Qatar University 
Tel.: 4403 4786 
Email : llCISsrizk@qu .e<:Ju , a& 
Dear Dr. Nasser Rlzk. 
Sub.: Research Ethics Review Exemption 
Dooem ber 16, 2013 
Ref.: Project tltledi Jrrhe regufatlon of Bm .. 3b In adlpocytes by glucose and 
insulin•' 
We would like to lnfonn you that your appllcaUon aJong wrth 1he supporting 
documents provided for the above proposal, is reviewed and having met all the 
requirements, has been exempted from the full ethics review. 
Please note that any changes/mod lficatlon or additions to the original subm llted 
protocol shOukl be reported to the committee to seek approval prior to 
continuatiOn. 
Voor Research Ethrcs Approval No. is: QU-&RB 269-EJ13 
Kindly refer ID this number In alt your future correspondence pert.arning to flfs 
project. 
Best wishes, 
Dr. Khalid Al-A i 
Chairperson. QU~IRB 
ln~tilul~onal Review Boilltd 
c laB) 
Offlce Of A..:•doemic laeat.:h 
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,.uo~ 
OATAII Ulll\'tiiS TY 
To: Dr. Nasser Rizk 
Department of Health Sciences 
Cc11ege of Atts and Science 
Dear Dr. Rizk, 
Subject: Reseanh grant# QUST.CAS·FALI ... J3/14.5 
Qatar U nlversltv 
Institutional Blo·safety Committee 
2S Da;1 2013 
Ref: Project dded "'The ~ ofBrn-Jb In adlpocytes by glucose and .Insulin~ 
We would like to i11fot'ln you that yow· applicatjon along wid~ supponing documents provided for 
the aho\'e prop<1511 have been t'C\'iewed by QU-IBC, and hu\'tJ18 met nlllhc rcquiremcntl!o, hus been 
granted approval for a period of one year and renewable for each year thereafl.etr~ should be sought 
1:1nd approved by QU-IBC period to continue. 
Plea.c;~ note lhBt QU-mC approval is contingent upon your OOherenoe to the following QU-IBC 
Guidelines: 
• Eruiuring oott~pliance with QU Safety Plans lltld app1icable national and international 
regulation . 
• Enswillg experiments that require plior IBC approval are not conducted untiliBC appt'Ovill is 
t.'!lbtain"d Bnd making initial d&enninalicm. of containment levels required for 
experiments. 
• Noti(ving the IBC of any chill1geli to other hazardouli material exp~riments previou.sJy 
approv~:d by the me. 
• Reporting any significant problems. vlolotion1 of QU Safety Plans and applicable 
regulation!ilguidelinea. or any significant rese~m:h-rcJated accidents and illnesSt:S to the 
QU·lBC. Also~ ensuring personnel receive appropriate orientation and specitic training for 
the safe performaru;c qf rhc work. 
Your TCKelllt!h approval No. tl'l : QU..IBC 3113;14. Please refer to this .up])Jl;)VHI number in all your fulure 
ootrespondenoe pertaining to this research. 
-Dr. Marnwan Abu-Mndl 
ChaiJJicm>n, QU-me 
Department of Health Sciences 
C"-o11ege of Artl5 & Sciences 
Qatat· University 
Tel: 974 4403 4791 
abumadl@qu.edu.qa 
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Appendix IV 
Results of preliminary studies found that Bm3b knockout mice had a higher body weights 
compared to normal mice. 
Figure 1: Loss of Brn-3bcause increased body mass and highbloodglucose in KO mutant mice 
(A) Body weight 
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A. Bm·3b KO mutants have increased body weight (red 
line; n=5) rhat is more pronounced in older an· FJs compared 
with age-mathed wild-type 1WT) contr littermates (blue; 
n=5) meas red at intemls up to 14 mltls. 
B. Bm.Jb KO mutant mice are profoundly glucose 
into lorant as shown by the eleva ted blood glucose after 
glucose tolerance testing (G TT) (red line) when com~red 
1'/lth WT com Is (blacli ltne). Bsseline bloat glucose l'IBS 
meas red a6er o1•ernight fe ·ng and a glucose bolus 1'/as 
adnt.nisrrated. alf.Jto rty blood glucose levels l',ere 
measured. Basei ne l:lood g ose (BG) 1•.as s•milar tn bot 
groups 30 min afrer g cose bolus, WT mice s wed the 
expected incre ase in BG, ••.hich ,. as reduced to basellfle by 2 
ho rs . Hol'le\-er Btn-3b KO mutants had significant~ higher 
ood gucose levels after 30 m· l',fl ich peaked et 1 hr 
remained elevated at 2 hours. In contrast, control groups 
demonstra ted increased blood gl cose at 30 min b l ol'ling 
bolus dose IOI'ted y a reduction ro basefne by 2 hrs 
Results of preliminary studies also have shown that Bm-3b mRNA expression extracted from 
peripheral blood is significantly reduced in patients with T2D compared with normal non-
diabetic controls. 
Fig ~: Qu.aatili.,at/Qn gf Bra-~12 from rlhQ.Ig bu.maa 12/ggd 
2.5 
c:: Blood was collected from normal 
·-Ul 2 subjects or T2D patients using PAX - • QI"C 
> 0 gene Blood RNA system (Qiagen). ! 01.5 
(-
' 
Following RNA extraction and eDNA 
.Q 
z Ql 1 I synthesis, quanfitafive real-time c.:_ E o 
' 
PCR was undertaken using Taq ~ ~0.5 
' 
man probes for POU4F2/Bm-3b. I 
c:: 0 • Differences in RNA were adjusted ~ m Normal T2D 
using house-keeping gene, PPIA. 
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